Cadila Healthcare gets FDA nod for phase 2(b)/3 trial of saroglitazar magnesium
Cadila Healthcare (Zydus Cadilla) said that it has obtained permission from the US Food and Drug Administration (FDA) to launch the phase 2(b)/3 clinical trial of saroglitazar magnesium in primary biliary cholangitis (PBC). The late-stage trial, designed to assess the efficacy and safety of saroglitazar magnesium, will have 192 patients. The participants will be randomly […]